Reportlinker Adds Gastrointestinal Pharmaceuticals: Technologies a...(LON CANCER 37 Colonic Polyps and (Con...),Health

Colonic Polyps and (Continued) 38

U.S. DEMOGRAPHICS 39

TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS 39

TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS) 40

FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS) 40

FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%) 41

PILL-SIZED VIDEO CAMERA 42

PILLCAM ESO 42

SMARTPILL 42

RADIO FREQUENCY IDENTIFICATION TECHNOLOGY 43

IPHONE APPLICATION 43

ENTERIC NERVOUS SYSTEM 43

INSURANCE COVERAGE 44

MONOCLONAL ANTIBODIES 45

WYETH IN SUIT WITH STATES 46

GENERIC INFLUENCE 46

BRANDED VS OTC PROTON PUMP INHIBITORS 47

MAIL ORDER TRENDS 48

MAIL ORDER TRENDS (CONTINUED) 49

Chapter-4: PRESCRIPTION PRODUCT SEGMENTS BY TYPE

ANTIDIARRHEALS 50

SYSTEMICALLY ACTING ANTIDIARRHEALS 51

OPIUM PRODUCTS 51

TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS 52

MARKET SIZE AND GROWTH 52

TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS) 53

FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS) 53

COMPETITIVE STRUCTURE AND MARKET SHARE 54

TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%) 54

FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS) 55

ANTIEMETICS 55

LOCALLY ACTING ANTIEMETICS 55

CENTRALLY ACTING ANTIEMETICS 56

ANTIDOPAMINERGICS 56

Antidopaminergics (Continued) 57

ANTICHOLINERGICS 58

MISCELLANEOUS ANTIEMETICS 58

Miscellaneous Antiemetics (Con
'/>"/>